Pathos AI Raises $237M at $3B Led by Bristol Myers, Adds Tempus Data and Alzheimer's Program

Pathos AI closed a $237M Series E at roughly $3B post-money on October 23, led by Bristol Myers Squibb and up from a $1.6B valuation in May 2025 — short of the $300M it was targeting. The company's Foundry model runs thousands of agents to score clinical candidates; it is expanding from oncology into neurology using new Tempus AI datasets, with the BMS partnership first focused on Alzheimer's.